- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Coagulation factor XI.
Displaying page 1 of 1.
EudraCT Number: 2011-000181-34 | Sponsor Protocol Number: OBI-1-301 | Start Date*: 2011-06-29 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies | |||||||||||||
Medical condition: Acquired Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003093-98 | Sponsor Protocol Number: Ten02 | Start Date*: 2015-02-24 |
Sponsor Name:Bio Products Laboratory Limited | ||
Full Title: A Phase III Open, Multicentre Study to Confirm the Safety, Pharmacokinetics and Efficacy of BPL’s High Purity Factor X in the Prophylaxis of Bleeding in Factor X Deficient Children Under the Age of... | ||
Medical condition: Factor X Deficiency | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002165-21 | Sponsor Protocol Number: ISIS416858-CS5 | Start Date*: 2017-11-23 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals Inc. | ||||||||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ISIS 416858 (IONIS-FXIRX an Antisense Inhibitor of Factor XI... | ||||||||||||||||||
Medical condition: Prevention of thrombosis while on hemodialysis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) CZ (Completed) AT (Completed) NL (Completed) BG (Completed) BE (Completed) GR (Completed) LV (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000565-40 | Sponsor Protocol Number: GLM101-002 | Start Date*: 2022-11-04 | |||||||||||
Sponsor Name:Glycomine, Inc | |||||||||||||
Full Title: A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participa... | |||||||||||||
Medical condition: PMM2-CDG | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
